Study of the Impact of Frequency of Changing PICCline Dressings in Patients With Acute Leukemia

Leukemia Clinical Trial

— LEUKA-PICC  

Official title:

Study of the Impact of Frequency of Changing PICCline Dressings in Patients With Acute Leukemia

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05793801
• Other study ID #: NIMAO/2021-2/JL-01
• Status: Recruiting
• Phase: N/A
• Start date: June 6, 2023
• Est. completion date: September 1, 2025

Study information

• Verified date: June 2023
• Source: Centre Hospitalier Universitaire de Nimes
• Contact: Éric JOURDAN, Dr.
• Phone: +334.66.68.32.34
• Email: Eric.jourdan[@]chu-nimes.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Peripherally Inserted Central Catheters have been widely used for many years for the administration of chemotherapy to patients with cancer. However, its use entails significant infectious complications and high risks of death.The hypothesis is that increasing the rate of PICCline dressing changes will reduce the occurrence of catheter-related infections.

Description:

The PICCline ("Peripherally Inserted Central Catheter") is a central catheter whose brachial insertion is peripheral. It has been widely used for many years for the administration of chemotherapy to patients with cancer. Although its use is growing (2.7 million applications in the USA in 2020), significant infectious complications (especially bacteremia) and even high risks of death are generally associated with it.

In December 2013, the French Society of Hospital Hygiene (SF2H) published a guide of "Recommendations for good practices and management of risks associated with PICC" to help professionals in the use of this device. It states that the rate of dressing repair is set at a maximum of 8 days for a sterile semipermeable transparent dressing; however, this recommendation is based on a questionable level of evidence (grade E level of evidence according to the HAS). In the appendix to this guide, the analysis of the scientific literature does not highlight any articles comparing different dressing repair rates. An observational study was conducted at the University Hospital of Nîmes, in order to determine the rate of infection on PICCline in the Hematology Department. In 2019, out of the 90 PICClines applied (dressing changes every 2 days), 12 infections (local and/or systemic) were noted, i.e. 13.3%.

In order to know the current practices of the different hematology services in France, a survey was conducted to collect protocols for PICCline dressing changes. A total of 23 haematology departments were contacted, 18 of which responded. The observation was made that, although most departments respected the SF2H recommendation (15 out of 18), others proposed different rhythms of care: (a) in the Hematology department at Nîmes University Hospital, dressings are redone every 48 hours, (b) in Montpellier, the frequency was 2 to 3 times a week, (c) in Grenoble, the use of PICCline was abandoned by the medical team who noted too many infections and thromboses associated with this device, and (d) in Toulouse and Strasbourg, the PICCline was used less and less for these same reasons. Moreover, the SF2H recommendations are addressed in a general way to professionals and valid for all patients; but no study can currently affirm that they are applicable to a fragile population of immunocompromised patients in the context of intensive chemotherapy. Hematology patients have a high risk of febrile neutropenia, of around 80%, and this risk of immunosuppression is a non-negligible point in terms of infection prevention during patient management.

In 2019 in France, the Réseau de Prévention des Infections Associées aux Soins launched a campaign to monitor and prevent infections associated with invasive devices. For 3 months, data on the occurrence of infectious episodes were collected in 1001 healthcare facilities. Of the nearly 12,000 bacteremia episodes identified, 25.4% were associated with an intravascular device, 17% of which were PICCline. Moreover, the survey revealed that the highest rates of occurrence were found in the Intensive Care Unit, Oncology and Hematology departments and the prevalence of bacteremia associated with intravascular devices in Hematology represented 39.8%.

Hypothesis : increasing the rate of PICCline dressing changes will reduce the occurrence of catheter-related infections.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: September 1, 2025
• Est. primary completion date: June 6, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patient with a diagnosis of acute myeloblastic leukemia.

• Patient going on intensive induction chemotherapy (causing a "high risk" situation of severe infection defined as profound neutropenia ( Polymorphonuclear neutrophil count <500/mm3) and lasting (>7 days).

• Patients who have had a PICCline placed within the last 24 hours or who require a PICCline placement as part of their hospitalization under optimal hygiene and asepsis conditions.

• Patient housed in a protected environment (flow chamber or Plasmair®).

• Patient who has given free and informed consent.

• Patient affiliated or beneficiary of a health insurance plan.

• Adult patient (=18 years old).

Exclusion Criteria:

• Patient with PICCline placed during a previous hospitalization.

• Patient in an exclusion period determined by another study.

• Patient under court protection, guardianship or curatorship.

• Patient unable to give consent.

• Patient for whom it is impossible to give informed information.

Related Conditions & MeSH terms

• Leukemia

Intervention

Other:
• Dressing change
The patient circuit corresponds to that of usual care. Not part of usual patient management: The rhythm of PICCline dressing changes, which differed between the two groups. The collection of pain on a visual analog scale at each dressing change.

Locations

Country	Name	City	State
France	CHU de Montpellier Hôpital St-Eloi	Montpellier

Sponsors (2)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nimes	University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Age of patients in the control group	In years	At the inclusion visit (- 48 hours to Day 0)
Other	Age of patients in the experimental group	In years	At the inclusion visit (- 48 hours to Day 0)
Other	Body Mass Index of patients in the control group	Body Mass Index = Weight ÷ (Height)2	At the inclusion visit (- 48 hours to Day 0)
Other	Body Mass Index of patients in the experimental group	Body Mass Index = Weight ÷ (Height)2	At the inclusion visit (- 48 hours to Day 0)
Other	Patients' medical history : control group	The medical history of each patient in the control group will be recorded.	At the inclusion visit (- 48 hours to Day 0)
Other	Patients' medical history : experimental group	The medical history of each patient in the experimental group will be recorded.	At the inclusion visit (- 48 hours to Day 0)
Other	Type of leukemia : control group	The type of leukemia of each patient in the control group will be recorded	At the inclusion visit (- 48 hours to Day 0)
Other	Type of leukemia : experimental group	The type of leukemia of each patient in the experimental group will be recorded	At the inclusion visit (- 48 hours to Day 0)
Other	Treatment start date : control group	The treatment start date of each patient in the control group will be recorded	At the inclusion visit (- 48 hours to Day 0)
Other	Treatment start date : experimental group	The treatment start date of each patient in the experimental group will be recorded	At the inclusion visit (- 48 hours to Day 0)
Other	Date when patients' aplasia started : control group	The date when each patient in the control group started aplasia will be recorded	At the inclusion visit (- 48 hours to Day 0)
Other	Date when patients' aplasia started : experimental group	The date when each patient in the experimental group started aplasia will be recorded	At the inclusion visit (- 48 hours to Day 0)
Other	Date when patients' aplasia ended : control group	The date when each patient in the control group ended their aplasia will be recorded	End of 2-month follow-up
Other	Date when patients' aplasia ended : experimental group	The date when each patient in the experimental group ended their aplasia will be recorded	At the end of the 2-month follow-up, on Day 60
Other	Date of hospital discharge : control group	The date when each patient in the control group was discharged from hospital will be recorded.	At the end of the 2-month follow-up, on Day 60
Other	Date of hospital discharge : experimental group	The date when each patient in the experimental group was discharged from hospital will be recorded.	At the end of the 2-month follow-up, on Day 60
Other	Antibiotic therapy provided : control group	The antibiotic therapy provided to each patient in the control group will be recorded	At the end of the 2-month follow-up, on Day 60
Other	Antibiotic therapy provided : experimental group	The antibiotic therapy provided to each patient in the experimental group will be recorded	At the end of the 2-month follow-up, on Day 60
Other	Presence of parenteral nutrition : control group	For each patient in the control group. Recorded as YES/NO	At the end of the 2-month follow-up, on Day 60
Other	Presence of parenteral nutrition : experimental group	For each patient in the experimental group. Recorded as YES/NO	At the end of the 2-month follow-up, on Day 60
Other	Occurrence of thrombosis on the PICCline : control group	For each patient in the control group : YES/NO and date	At the end of the 2-month follow-up, on Day 60
Other	Occurrence of thrombosis on the PICCline : experimental group	For each patient in the experimental group : YES/NO and date	At the end of the 2-month follow-up, on Day 60
Other	Device related data : control group	Device-related data: number and types of previous central lines, history of infection, type of device, number of lines, type of fixation, type of dressing, device use protocols, description of puncture site appearance, related intercurrent events, identified germs will be recorded for each patient in the control group.	At the end of the 2-month follow-up, on Day 60
Other	Device related data : experimental group	Device-related data: number and types of previous central lines, history of infection, type of device, number of lines, type of fixation, type of dressing, device use protocols, description of puncture site appearance, related intercurrent events, identified germs will be recorded for each patient in the experimental group.	At the end of the 2-month follow-up, on Day 60
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in controls	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 1+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in controls	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 9+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in controls	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 17+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in controls	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 25+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in controls	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 32+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in controls	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 39+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in controls	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 46+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in controls	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 53+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in controls	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 60+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 1+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 3+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 5+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 7+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 9+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 11+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 13+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 15+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 17+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 19+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 21+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 23+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 25+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 27+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 29+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 31+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 33+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 35+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 37+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 39+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 41+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 43+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 45+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 47+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 49+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 51+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 53+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 55+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 57+48 hours
Primary	Rate of local and/or systemic occurrence of infection on the PICCline in the experimental group	Occurrence of infection on the PICCline, local and/or systemic, and its time of occurrence according to the definition of the Technical Committee on Nosocomial Infections and Healthcare-Associated Infections (CTINILS) during intensive treatment, from the beginning of induction chemotherapy to the beginning of the first consolidation. Local infection will be recorded from the time of PICCline placement, and systemic infection will be recorded when it occurs.	Day 59+48 hours
Secondary	Pain or discomfort generated by PICCline dressing changes in controls	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 1
Secondary	Pain or discomfort generated by PICCline dressing changes in controls	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 9
Secondary	Pain or discomfort generated by PICCline dressing changes in controls	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 17
Secondary	Pain or discomfort generated by PICCline dressing changes in controls	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change.	Day 25
Secondary	Pain or discomfort generated by PICCline dressing changes in controls	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 32
Secondary	Pain or discomfort generated by PICCline dressing changes in controls	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 39
Secondary	Pain or discomfort generated by PICCline dressing changes in controls	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 46
Secondary	Pain or discomfort generated by PICCline dressing changes in controls	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 53
Secondary	Pain or discomfort generated by PICCline dressing changes in controls	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 60
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 1
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 3
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 5
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 7
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 9
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 11
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 13
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 15
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 17
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 19
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 21
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 23
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 25
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 27
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 29
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 31
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 33
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 35
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 37
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 39
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 41
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 43
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 45
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 47
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 49
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 51
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 53
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 55
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 57
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 59
Secondary	Pain or discomfort generated by PICCline dressing changes in the experimental group	The patient will be asked to evaluate pain according to a visual analog scale following each dressing change. On this scale, absence of pain = 0 mm and maximum pain imaginable = 100 mm.	Day 61
Secondary	Length of time in hospital in controls	The duration of time in hospital will be measured from the first day of receiving chemotherapy until transfer towards a healthcare facility for follow-up and rehabilitation or return home.	At the end of hospitalization
Secondary	Length of time in hospital in the experimental group	The duration of time in hospital will be measured from the first day of receiving chemotherapy until transfer towards a healthcare facility for follow-up and rehabilitation or return home.	At the end of hospitalization
Secondary	Bacterial species isolated after cytobacteriological analysis of samples (blood cultures and PICCline) and sensitivity to antibiotics in controls	If an infection on the PICCline is suspected, the device will be removed and blood cultures will be taken from the PICCLine and the periphery. If the PICCline culture is positive and the blood cultures negative, the infection is local and device-related. If the PICCline culture and peripheral blood cultures are positive, then catheter-related bacteremia is diagnosed. If general signs like fever appear in a patient with a PICCline without local signs of infection, then blood taken from the periphery and blood from the PICCLine will be cultured. If both blood cultures are positive, catheter-related bacteremia is highly probable. If the blood culture bottle taken from the periphery remains negative and there is a strong suspicion of infection related to the PICCline, then new blood cultures from the periphery and from the device will be performed in order to be able to conclude that there is bacteremia/device colonization/contamination.	At the end of the 2-month follow-up, on Day 60
Secondary	Bacterial species isolated after cytobacteriological analysis of samples (blood cultures and PICCline) and sensitivity to antibiotics in the experimental group	If an infection on the PICCline is suspected, the device will be removed and blood cultures will be taken from the PICCLine and the periphery. If the PICCline culture is positive and the blood cultures negative, the infection is local and device-related. If the PICCline culture and peripheral blood cultures are positive, then catheter-related bacteremia is diagnosed. If general signs like fever appear in a patient with a PICCline without local signs of infection, then blood taken from the periphery and blood from the PICCLine will be cultured. If both blood cultures are positive, catheter-related bacteremia is highly probable. If the blood culture bottle taken from the periphery remains negative and there is a strong suspicion of infection related to the PICCline, then new blood cultures from the periphery and from the device will be performed in order to be able to conclude that there is bacteremia/device colonization/contamination.	At the end of the 2-month follow-up, on Day 60